The cost‐effectiveness of solifenacin vs fesoterodine, oxybutynin immediate‐release, propiverine, tolterodine extended‐release and tolterodine immediate‐release in the treatment of patients with overactive bladder in the UK National Health Service

Abstract

Solifenacin provided the greatest clinical benefit and associated QALYs for all three outcomes of interest across all therapies considered, and to be either dominant or cost-effective relative to all other new-generation agents, but not cost-effective relative to oxybutynin for frequency and incontinence.